Last reviewed · How we verify
Ropivacaine + Ketamine
Ropivacaine blocks sodium channels to provide local anesthesia, while ketamine blocks NMDA receptors to provide analgesia and dissociative effects, together reducing pain and anesthetic requirements.
Ropivacaine blocks sodium channels to provide local anesthesia, while ketamine blocks NMDA receptors to provide analgesia and dissociative effects, together reducing pain and anesthetic requirements. Used for Local and regional anesthesia with enhanced analgesia, Perioperative pain management.
At a glance
| Generic name | Ropivacaine + Ketamine |
|---|---|
| Sponsor | Aga Khan University |
| Drug class | Local anesthetic + NMDA receptor antagonist combination |
| Target | Voltage-gated sodium channels (ropivacaine); NMDA receptor (ketamine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing action potential propagation and sensory transmission. Ketamine is a non-competitive NMDA receptor antagonist that provides analgesia, amnesia, and dissociation. The combination leverages synergistic analgesic and anesthetic effects, allowing lower doses of each agent and potentially reducing adverse effects associated with higher single-agent doses.
Approved indications
- Local and regional anesthesia with enhanced analgesia
- Perioperative pain management
Common side effects
- Dissociation
- Dizziness
- Nausea
- Local anesthetic toxicity (at high doses)
- Cardiovascular effects
Key clinical trials
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
- Perioperative Multimodal General AnesTHesia Focusing on Specific CNS Targets in Patients Undergoing carDiac surgERies (NA)
- Superficial Cervical Plexus Block Versus Ketamine in the Prevention of Chronic Pain After Thyroidectomy (PHASE4)
- Supra Inguinal Fascia Iliaca Block as Rescue Analgesia Following Total Hip Arthroplasty (NA)
- Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia (PHASE4)
- PVB vs Ketamine/Lidocaine in Rib Fracture Patients (EARLY_PHASE1)
- Paravertebral Nerve Blocks in Neonates (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine + Ketamine CI brief — competitive landscape report
- Ropivacaine + Ketamine updates RSS · CI watch RSS
- Aga Khan University portfolio CI